Healthcare

Selected direction.

Pay for readiness, necessary care and verified health outcomes

A lower bill is not a success if it comes from denying necessary care, shifting costs, or weakening future capacity.

The proposal. Pay for verified readiness, fund necessary care, and reward independently verified health, function, and safety at the lowest sustainable total cost. Pursue resource efficiency and constraints on excessive prices together. Use need-adjusted population care budgets and stable, competitive clinician salaries.

How it would work. Fund readiness separately against verified staffing, equipment, maintenance, reserves, drills, and backup. Provide catastrophic-risk pooling and independent review with additional funding when necessary care exceeds a local budget; exhaustion must not automatically mean denial. Reward durable improvement, preservation of function, and prevention of deterioration, including for chronic illness and disability. Better health may deserve recognition before it saves money. Share only independently verified systemwide net savings after quality, access, and safety requirements, allocating part to staff and reinvestment and part to lower future premiums or tax-funding needs. Use prospective benchmarks, delayed verification of part of bonuses, and multiyear prevention investment.

Implementation. Choose ownership, insurer roles, administration, eligibility, covered care, patient costs, funding rates, savings shares, evaluators, legal authority, and transition. Protect patient choice and appeal; measure waits, unmet need, follow-up, and outcomes for people leaving care. Prevent patient selection, coding manipulation, inflated baselines, and cost shifting. Independently measure harm, protect honest reporting, and hold concealment and recklessness accountable. Reconcile reliable funding with taxpayer consent; neither savings sufficiency nor contribution-proportional entitlement is established. Further inquiry includes mental health, prevention, humane facilities and nature, pharmaceutical conflicts, and supplement purity.

Read this alongside The Framework and the Working Guide.

Selected direction.

End pharmaceutical advertising

Pharmaceutical promotion raises a separate policy question from how necessary healthcare is paid for and evaluated.

The proposal. End pharmaceutical advertising. The direction is selected; its exact scope is not.

How it would work. Define whether the prohibition covers direct-to-consumer prescription-drug advertising or all pharmaceutical advertising. The framework has not selected between those scopes.

Implementation. Specify covered products, audiences, media, exceptions, legal authority, enforcement and transition. Evaluate evidence and effects without assuming that every pharmaceutical communication or product is harmful. This proposal is distinct from both healthcare payment reform and election-advertising restrictions.

Read this alongside The Framework and the Working Guide.

Open question. This is an open question. No substantive policy has been selected.

Further health and pharmaceutical policy

Healthcare payment reform does not settle prevention, pharmaceutical research or product standards.

The question. Prevention/mental health, humane facilities, research conflicts/liability and supplement standards.

How to develop it. Identify what currently works, establish any concrete problem and examine evidence, affected people, rights, costs and alternatives before selecting reform. No complete policy for this subject has been adopted.

Read this alongside The Framework and the Working Guide.